Clinical evidence indicates that Adeno-Associated Virus (AAV) vector-mediated Apolipoprotein A-I Binding Protein (AIBP) gene therapy exhibits regulatory effects on retinal cholesterol metabolism and neuroprotective effects in experimental glaucoma (Ju et al., 2025). Here, NAXE is linked to glaucoma.